Evofem Biosciences, Inc.
EVFM
$0.01
$0.00-8.54%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 899.00K | 9.56M | 4.95M | 4.83M | 845.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 899.00K | 9.56M | 4.95M | 4.83M | 845.00K |
| Cost of Revenue | 410.00K | 2.59M | 905.00K | 755.00K | 365.00K |
| Gross Profit | 489.00K | 6.97M | 4.05M | 4.07M | 480.00K |
| SG&A Expenses | 4.47M | 3.16M | 4.48M | 4.47M | 4.97M |
| Depreciation & Amortization | 75.00K | 89.00K | 80.00K | 107.00K | 223.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.47M | 6.22M | 5.93M | 6.08M | 518.00K |
| Operating Income | -4.57M | 3.35M | -982.00K | -1.25M | 327.00K |
| Income Before Tax | -5.47M | 2.79M | -1.57M | -1.78M | 956.00K |
| Income Tax Expenses | -1.00K | -1.00K | -4.00K | 7.00K | -- |
| Earnings from Continuing Operations | -5.47M | 2.79M | -1.57M | -1.78M | 956.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.47M | 2.79M | -1.57M | -1.78M | 956.00K |
| EBIT | -4.57M | 3.35M | -982.00K | -1.25M | 327.00K |
| EBITDA | -4.49M | 3.44M | -898.00K | -1.14M | 556.00K |
| EPS Basic | -0.04 | 0.02 | -0.01 | -0.02 | 0.01 |
| Normalized Basic EPS | -0.03 | 0.01 | -0.02 | -0.01 | 0.01 |
| EPS Diluted | -0.04 | 0.00 | -0.01 | -0.02 | 0.00 |
| Normalized Diluted EPS | -0.03 | 0.00 | -0.02 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 133.25M | 145.94M | 119.58M | 115.69M | 118.16M |
| Average Diluted Shares Outstanding | 133.25M | 25.34B | 119.58M | 115.69M | 6.16B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |